US20070141245A1 - System and method for coating filaments - Google Patents
System and method for coating filaments Download PDFInfo
- Publication number
- US20070141245A1 US20070141245A1 US11/638,982 US63898206A US2007141245A1 US 20070141245 A1 US20070141245 A1 US 20070141245A1 US 63898206 A US63898206 A US 63898206A US 2007141245 A1 US2007141245 A1 US 2007141245A1
- Authority
- US
- United States
- Prior art keywords
- coating
- suture line
- coating tube
- tube
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011248 coating agent Substances 0.000 title claims abstract description 174
- 238000000576 coating method Methods 0.000 title claims abstract description 172
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000008199 coating composition Substances 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims description 61
- 239000002904 solvent Substances 0.000 claims description 39
- 238000011049 filling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000007664 blowing Methods 0.000 claims 1
- -1 poly(hydroxybutyrate) Polymers 0.000 description 24
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000012867 bioactive agent Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000919 ceramic Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 5
- 238000003618 dip coating Methods 0.000 description 5
- 229940071209 stearoyl lactylate Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052788 barium Inorganic materials 0.000 description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229910052792 caesium Inorganic materials 0.000 description 3
- 238000003490 calendering Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229910052730 francium Inorganic materials 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229910052701 rubidium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000003916 calcium stearoyl-2-lactylate Substances 0.000 description 2
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 2
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- KLMCZVJOEAUDNE-UHFFFAOYSA-N francium atom Chemical compound [Fr] KLMCZVJOEAUDNE-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 101800004361 Lactoferricin-B Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000002944 hormone and hormone analog Substances 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 150000002943 palmitic acids Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229940099765 pipracil Drugs 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001849 poly(hydroxybutyrate-co-valerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- GTNNCNWLWZLCGV-UHFFFAOYSA-M potassium;2-(2-octadecanoyloxypropanoyloxy)propanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O GTNNCNWLWZLCGV-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- YSVXTGDPTJIEIX-UHFFFAOYSA-M silver iodate Chemical compound [Ag+].[O-]I(=O)=O YSVXTGDPTJIEIX-UHFFFAOYSA-M 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
- MNMYRUHURLPFQW-UHFFFAOYSA-M silver;dodecanoate Chemical compound [Ag+].CCCCCCCCCCCC([O-])=O MNMYRUHURLPFQW-UHFFFAOYSA-M 0.000 description 1
- LTYHQUJGIQUHMS-UHFFFAOYSA-M silver;hexadecanoate Chemical compound [Ag+].CCCCCCCCCCCCCCCC([O-])=O LTYHQUJGIQUHMS-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/20—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to wires
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06B—TREATING TEXTILE MATERIALS USING LIQUIDS, GASES OR VAPOURS
- D06B3/00—Passing of textile materials through liquids, gases or vapours to effect treatment, e.g. washing, dyeing, bleaching, sizing, impregnating
- D06B3/04—Passing of textile materials through liquids, gases or vapours to effect treatment, e.g. washing, dyeing, bleaching, sizing, impregnating of yarns, threads or filaments
- D06B3/045—Passing of textile materials through liquids, gases or vapours to effect treatment, e.g. washing, dyeing, bleaching, sizing, impregnating of yarns, threads or filaments in a tube or a groove
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00889—Material properties antimicrobial, disinfectant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
Definitions
- the present disclosure relates generally to filament coating systems and methods, more specifically to systems and methods for coating sutures.
- Surgical sutures are primarily used during surgery to stitch together sections of tissue to aid in post-surgical healing.
- Sutures are often coated with various substances to improve their knot tie-down characteristics.
- coating increases suture's surface lubricity which reduces the friction associated with passing of the suture through the tissue, thereby reducing tissue trauma.
- Conventionally, suture coatings have been applied by dipping, bushing, wiping, spraying or drip coating.
- Dip coating involves submergence of a suture line into a coating composition contained in a vessel.
- dip coating involves the use of multiple guiding means (e.g., rollers) to pass the suture through the coating composition.
- a horizontally passing suture needs to be directed downward into and upward out of the vessel containing the coating composition.
- at least one of the guiding roller(s) is positioned within the coating vessel, in contact with the suture before the line is dried. This contact by the roller frequently removes coating material from the suture, thereby reducing the effectiveness of the coating.
- Coating has also been accomplished using filling heads. This method involves passing a suture line through a V-shaped notch. Coating composition injected into the notch contacts and coats the suture line. The suture line does not come in contact with guiding rollers until after the coating dries. Although the coating system using filling heads provides more consistent coating for the suture line, the contact time for coating solution to penetrate into suture is significantly less (e.g., less that 0.1 second) than that provided by the conventional dipping coating mechanisms.
- a system and method for coating a suture line are disclosed.
- the system includes an elongated coating tube having coater heads disposed at both ends thereof.
- the suture line is fed into the coating tube through an opening in one of the coater heads and exits the coating tube through an opening in the other coater head.
- Guide rollers that contact the un-coated suture ensure alignment of the suture line as it enters the coating tube.
- the coating tube is filled with a coating composition to a level above the entry point of the suture line.
- the composition pours through the openings of the coating tube and is collected by the coater heads so that it is circulated during the coating process to ensure proper ratio of coating agent to solvent.
- the suture line After exiting the coating tube, the suture line passes through a dryer and then is guided by a set of rollers to a winding roll. Then, the suture contacts guide rollers only after exiting the dryer, thereby helping to ensure a uniform coating.
- a system for coating a suture line includes a first guide positioned to orient the suture line for entry into a coating tube.
- the system also includes a coating tube having an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube.
- the coating tube includes a fill opening through which a coating composition is introduced into the coating tube to a level sufficient to submerge a portion of the suture line.
- the system further includes a second guide positioned to orient the suture line exiting from the dryer.
- a method for coating at least one suture line includes the step of orienting the suture line through a first guide for entry into a coating tube.
- the coating tube includes an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube.
- the coating tube further includes one or more fill openings through which a coating composition is introduced into the coating tube a level sufficient to submerge a portion of the suture line.
- the method also includes the steps of submerging the suture line in the coating composition filling the coating tube as well as orienting the suture line exiting from the dryer through a second guide.
- a system for coating at least one suture line includes a first guide positioned to orient the suture line for entry into a coating tube having an inlet opening to admit the suture line passing through the first guide and an outlet opening through which the suture line exits the coating tube.
- the coating tube also includes at least one fill opening through which a coating composition is introduced into the coating tube to at least a level sufficient to submerge at least one portion of the suture line, such that the coating composition flows out through at least one of the inlet and outlet openings.
- the system also includes at least one coater head disposed at each of end of the coating tube, the first and second coater head configured to collect the coating composition flowing through the inlet and outlet openings and a second guide positioned to orient the suture line exiting the coating tube.
- FIG. 1 is a schematic diagram of a dip suture coating system according to one embodiment of the present disclosure
- FIG. 2 is a schematic diagram of a dip coater according to the present disclosure
- FIG. 3 is a schematic diagram of a distal coater head useful in embodiments of coating systems according to the present disclosure
- FIG. 4 is a sectional view of a dip coating tube according to the present disclosure.
- FIG. 5 is a flow diagram of a method for coating a suture line according to the present disclosure.
- the present disclosure provides for a horizontal dip coating system.
- the system includes one or more input winders inputting a suture line into a dip coater using a first set of one or more guiding rollers.
- the dip coater includes a coating tube positioned horizontally with a coater head disposed at proximal and distal ends thereof.
- the coating tube and the coater heads include openings through its centers to allow for the suture line to pass horizontally therethrough.
- a coating composition fills the coating tube above the openings of the coating tube through which the suture line passes to coat the line. Any coating composition that leaks out of the coating tube is collected by the coater heads.
- the coating composition is injected at a higher rate than it leaks out to maintain the composition level therein.
- the coating composition collected by the coater heads is circulated throughout the dip coater.
- solvent content of the coating composition is-monitored and adjusted to ensure that a predetermined ratio of coating agent to solvent is maintained.
- the suture line is dried and thereafter the line is guided by a second set of one or more rollers to winding rolls.
- FIG. 1 shows a horizontal dip coating system 1 according to the present disclosure for coating a plurality of suture lines simultaneously.
- the coating system 1 includes at least one input winder 2 for passing at least one suture line 10 through a dip coater 3 , an air wiper 5 , a dryer 6 , and an air cooler 7 . Thereafter the line 10 is wound by at least one take-up winder 8 , which may be part of a pull-over loading station 9 . It is envisioned that the pull-over loading station pulls the line 10 through the coating system 1 . As the line 10 passes through the dip coater 3 it is submerged in a coating composition in order to absorb coating materials.
- the coating system shown in FIG. 1 includes multiple input winders and multiple take-up winders. Also, it is contemplated that each input winder and/or take-up winder may handle one or more than one suture lines (e.g., in FIG. 1 each winder handles two suture lines).
- the input winder(s) 2 disperses the line 10 which may be a monofilament or a multifilament braided suture.
- the line 10 Prior to dispersing, the line 10 may be prepared for coating which may involve calendaring the line 10 to facilitate penetration of the coating composition into the interstices of the braid suture, especially where the present system is used to apply a second or third composition to the suture line.
- An example of a calendaring apparatus and method thereof is disclosed by commonly owned U.S. Pat. No. 5,312,642 entitled “Method and Apparatus for Calendering and Coating/Filling Sutures” which is hereby incorporated by reference in its entirety herein.
- the system 1 also includes the air wiper 5 and the air cooler 7 .
- the air wiper 5 is positioned between the dip coater 3 and the dryer 6 and is configured to blow gas (e.g., air, nitrogen, etc.) on the passing line 10 to blow off excess composition.
- the air cooler 7 is positioned between the dryer 6 and the take-up winder 8 and is configured to blow cool air on the line 10 to provide cooling for the dried line.
- FIG. 2 shows in more detail a dip coater 3 and the dryer 6 in accordance with an embodiment of the present disclosure.
- the line 10 is passed through the dip coater 3 so that it is immersed in a coating composition.
- the line 10 is guided into the dip coater 3 around a first set of rollers 13 (e.g., rollers 12 and 14 ) and passed horizontally through a coating tube 24 which is filled with a coating composition 31 containing the dissolved coating agent.
- the dip coater 3 may be configured to coat a plurality of lines 10 .
- the dip coater 3 may have a plurality of coating tubes 24 corresponding to the number of lines 10 .
- the coating tube 4 may be substituted by a container configured to coat multiple lines 10 .
- the coating tube 24 is positioned horizontally and may have a cylindrical shape and may be approximately 1′ to 10′ in length. Typically, the coating tube is 3′ to 5′ long.
- the coating tube 24 is preferably manufactured from stainless steel material that does not react with the coating composition.
- the coating tube may be glass or glass-lined.
- the outer diameter of tube can vary depending on a number of factors such as the number of filaments being treated, the particular coating composition being applied and the desired contact time between the composition and the suture line.
- the cylindrical shape is merely only one embodiment of the coating tube 24 and that it may have a variety of shapes (e.g., rectangular, triangular, or hexagonal cross-sectional shapes, etc.).
- the line 10 enters the coating tube 24 through a proximal coater head 18 which is discussed in more detail below with reference to a distal coater head 20 , both of which have a circular cross section. It is envisioned that the line 10 passes through dip coater 3 through an opening 91 of the proximal coater head 18 , an opening 92 of the coating tube 24 , an opening 93 of the coating tube 24 and an opening 94 of the distal coater head 20 .
- the openings 91 , 92 , 93 , 94 are preferably drilled through the center of surfaces 95 , 96 , 97 , 98 respectively, of ceramic eyelets disposed within the proximal and distal coater heads 18 , 20 and the coating tube 24 as shown in FIG. 3 and discussed in more detail below.
- the openings may be drilled in a plurality of ways (e.g., a laser) to achieve a straight path for the line 10 through the dip coater 3 .
- the coating tube 24 is filled with a coating composition 31 through a supply tube 56 which is connected thereto via adapter 60 having a male national pipe thread (MNPT) or another type of connecting means.
- the adapter 60 may be coupled to the coating tube 24 at an angle (e.g., a 135° angle) with the longitudinal axis of the coating tube 24 at the top portion thereof.
- the tubing used to interconnect the components of the dip coater 3 e.g., the supply tube 56 and other tubing discussed below
- the supply tube 56 is made from PTFE and has a 3 ⁇ 8′′ diameter.
- the coating composition 31 is carried into the coating tube 24 via a circulating pump 34 which withdraws the composition 31 from a tank 28 through a tube 58 .
- the tank 28 preferably includes a stirring device, such as a magnetic stirrer driver 26 positioned thereunder, to prevent settling or other separation of the components of the coating composition.
- FIG. 3 shows a cross sectional view of the distal coater head 20 along the vertical axis of the coating tube 24 .
- the coating tube 24 is filled with the composition 31 to a level which is at least above the line 10 (e.g., above the center of the coating tube 24 ) to ensure that the line 10 is immersed in the composition 31 as the line 10 passes through the coating tube 24 . Since the composition 31 fills the coating tube 24 above the opening 93 , composition 31 may leak therethrough and be collected in the proximal and distal coater heads 18 , 20 . As a result of composition 31 leaking out of the coating tube 24 , the in-flow must equal or exceed out-flow. Therefore, the composition 31 will be circulated (e.g., continually supplied into the coating tube 24 ) to maintain a steady state, where the level of the composition 31 is continuously above the openings 92 , 93 .
- the assembly 20 includes a removable reducing tee 80 configured to drain leaking composition 31 .
- the reducing tee 80 can advantageously have an outer diameter larger than the outer diameter of the coating tube 24 so that the tee 80 fits over the coating tube 24 .
- the return adapter 22 is the reducing portion of the reducing tee 80 and preferably includes an MNPT connection.
- the removable tee 80 is connected to the coating tube 24 .
- the distal coater head 20 includes two ceramic eyelets 72 , 74 .
- the ceramic eyelet 72 is positioned at the distal end of the coating tube 24 within the reducing tee 80 and the ceramic eyelet 74 is attached at the distal end of the reducing tee 80 .
- the ceramic eyelets 72 , 74 are designed to optimize alignment of the openings 93 , 94 while minimizing the solvent lost during the coating process as discussed in more detail below.
- the proximal coater head 18 includes the same components (e.g., ceramic eyelet, o-ring, etc.) assembled in the same manner as discussed above with regard to the distal coater head 20 .
- the composition 31 out-flows through return adapters 21 , 22 coupled to the bottom portion of the proximal and distal coater heads 18 , 20 respectively and return tubes 45 , 42 to a return tank 32 .
- the return tank 32 collects any excess composition 31 present in the coating tube 24 through an overflow adapter 40 which is coupled to the upper portion thereof.
- the overflow adapter 40 Upon reaching the overflow adapter 40 , the excess coating composition 31 flows through a return tube 44 to the return tank 32 and mixes with return composition 33 .
- the outlet of overflow adapter 40 is also used to determine when the composition 31 filled the coating tube 24 to the desired level.
- the overflow adapter 40 is positioned above the openings 91 , 92 , 93 , 94 hence when composition 31 reaches the overflow adapter 40 and flows therethrough and into the return tank 32 . This ensures that the suture line 10 is submerged inside the coating tube 24 .
- FIG. 4 shows a cross sectional view along the section line 4 of the coating tube 24 .
- Adapter 60 and adapter 54 are shown positioned on the upper portion of the coating tube 24 while the drain valve 46 is positioned on the bottom portion thereof.
- the overflow adapter 40 is positioned on the upper portion of the coating tube 24 as well, slightly below the adapters 54 , 60 .
- the drain valve 46 may be used to empty coating tube 24 of the coating composition 31 upon shut down of the coating system 1 for maintenance or once the coating process is finished.
- the return composition 33 may be recycled during the coating process. Typically, a portion of any volatile solvent in the coating composition may evaporate during the coating process before excess composition 31 flows to the return tank 32 .
- the return composition 33 is contained within the coating system 1 by a plurality of tubes and adapters discussed above to contain the return composition 33 and to minimize solvent loss and vapor escape. Some vapor which does escape is vented through vent headers (not shown) installed above the coating tube 24 .
- a controller 48 can be connected to the return tank 32 and configured to test the density and/or viscosity of the return composition 33 using, e.g., a mass flow meter. If the density/viscosity of the return composition 33 exceeds a predetermined level (e.g., density of the original composition 31 ) then the controller 48 signals that the composition needs to be adjusted e.g., by injecting additional solvent carrier 35 directly into the coating tube 24 or into the return tank 32 .
- a predetermined level e.g., density of the original composition 31
- the controller 48 is electrically connected to a solvent pump 96 (e.g., solvent supply means) which injects solvent 35 into the coating tube 24 and a control valve 50 adjusts the flow of the solvent 35 into the return tank 32 .
- the solvent 35 can be injected into the coating tube 24 through the solvent adapter 54 connected to the solvent tank 36 through a tube 52 .
- the solvent adapter 54 is positioned at an angle (e.g., a 45° angle) with the longitudinal axis of the coating tube 24 at the top portion thereof while the drain valve 46 is positioned on the bottom portion thereof.
- the return tank 32 includes a magnetic stirrer driver 30 to maintain uniformity of the coating composition throughout the return composition 33 and to mix any added solvent 35 .
- return tank 32 supplies the return composition 33 to tank 28 where it is recycled and continually pumped into the coating tube 24 .
- FIG. 5 shows a method for coating the suture line 10 using the coating system 1 of the present disclosure.
- step 150 the coating tube 24 is filled with the composition 31 above the openings 92 , 93 to ensure that as the line 10 is submerged in the composition 31 .
- the composition 31 is continually fed into the coating tube 24 at a rate which is equal to or slightly exceeds the rate at which the composition 31 leaks through the openings 92 , 93 . This allows the level of the composition 31 to stay above the openings 92 , 93 despite the loss of the composition 31 .
- only the level of the composition 31 must be controlled during the coating process, whereas, conventional coating techniques, which depend on point coating, require precise control of the flow rate of the coating composition.
- step 152 excess composition 31 is collected. This is accomplished by collecting the composition 31 from the proximal and distal coater heads 18 , 20 which are configured to catch excess liquid and from the overflow adapter 40 which prevents overfilling of the coating tube 24 by providing a flow path for any excess composition 31 .
- the excess composition 31 flows to the return tank 32 .
- the controller 48 analyzes the density/viscosity of return composition 33 to determine whether additional solvent 35 needs to be added. If the density is above the desired limit (e.g., the coating agent to solvent ratio within the return composition 33 is larger than that ratio within the composition 31 ) then in step 156 , the controller 48 adjusts the solvent content.
- Adjustment of solvent level can be accomplished by signaling the solvent pump 96 which injects the solvent 35 into the coating tube 24 and/or opening the control valve 50 to add solvent 35 into the return composition 33 .
- the return composition 33 is then added into tank 28 from where it is continuously injected into coating tube 24 .
- each portion of the suture line 10 should reside within the coating tube 24 approximately between 0.5 second to 10 minutes, preferably the residence time is about 1 minute.
- the line 10 As the line 10 the dip coater 3 the line 10 enters the dryer 6 and in step 158 , the line 10 is dried.
- the drying temperature depends on the coating composition used and may range approximately between the ambient room temperature (e.g., 25° C.) at the low extreme and above 100° C. at the upper extreme. It is also envisioned that the dryer 6 uses heated gas (e.g., air, nitrogen, etc.) to dry the line 10 .
- step 160 the line 10 is cooled by the air cooler 7 , which blows cool air onto the dried line 10 and thereafter the line 10 is guided by a second set of rollers 39 (e.g., a roller 38 ) into the winder 8 where it is wound.
- a second set of rollers 39 e.g., a roller 38
- the present disclosure allows the line 10 to avoid physical contact with various machine parts during the coating process (e.g., guiding rollers).
- the line 10 comes in contact only with the coating composition between the time it is fed into the dip coater 3 and the time it is wound on the winder 8 . This is due to the horizontal positioning of the coating tube 24 and the horizontal orientation of the line 10 therethrough, which allows the line 10 to avoid physical contact with components by using a minimal amount of guiding mechanisms (e.g., guiding rollers 13 , 39 )
- the coating composition can be a solution, dispersion, emulsion containing, for example, one or more polymeric materials and/or one or more bioactive agents.
- the coating composition includes a polymer, or a combination of polymers.
- the polymer is most suitably biocompatible, including polymers that are non-toxic, non-inflammatory, chemically inert, and substantially non-immunogenic in the applied amounts.
- the polymer may be either bioabsorbable or biostable. A bioabsorbable polymer breaks down in the body. Bioabsorbable polymers are gradually absorbed or eliminated by the body by hydrolysis, metabolic process, bulk, or surface erosion.
- bioabsorbable materials include but are not limited to polycaprolactone (PCL), poly-D, L-lactic acid (DL-PLA), poly-L-lactic acid (L-PLA), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly (amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates.
- PCL polycaprolactone
- DL-PLA L-lactic acid
- L-PLA poly-L-lactic acid
- L-PLA poly(lactide-co-
- Biomolecules such as heparin, fibrin, fibrinogen, cellulose, starch, and collagen are typically also suitable.
- a biostable polymer does not break down in the body, and thus a biostable polymer is present in the body for a substantial amount of time after implantation.
- biostable polymers include PARYLENETM, PARYLASTTM, polyurethane (for example, segmented polyurethanes such as BIOSPANTM), polyethylene, polyethlyene teraphthalate, ethylene vinyl acetate, silicone, polyethylene oxide, and polytetrafluoroethylene (PTFE).
- the coating compositions of the present disclosure may also include a fatty acid component that contains a fatty acid or a fatty acid salt or a salt of a fatty acid ester.
- Suitable fatty acids may be saturated or unsaturated, and include higher fatty acids having more than about 12 carbon atoms.
- Suitable saturated fatty acids include, for example, stearic acid, palmitic acid, myristic acid and lauric acid.
- Suitable unsaturated fatty acids include oleic acid, linoleic acid, and linolenic acid.
- an ester of fatty acids such as sorbitan tristearate or hydrogenated castor oil, may be used.
- Suitable fatty acid salts include the polyvalent metal ion salts of C6 and higher fatty acids, particularly those having from about 12 to 22 carbon atoms, and mixtures thereof.
- Fatty acid salts including the calcium, magnesium, barium, aluminum, and zinc salts of stearic, palmitic and oleic acids may be useful in some embodiments of the present disclosure.
- Particularly useful salts include commercial “food grade” calcium stearate which consists of a mixture of about one-third C16 and two-thirds C18 fatty acids, with small amounts of the C14 and C22 fatty acids.
- Suitable salts of fatty acid esters which may be included in the coating compositions applied in accordance with the present disclosure include calcium, magnesium, aluminum, barium, or zinc stearoyl lactylate; calcium, magnesium, aluminum, barium, or zinc palmityl lactylate; calcium, magnesium, aluminum, barium, or zinc olelyl lactylate; with calcium stearoyl-2-lactylate (such as the calcium stearoyl-2-lactylate commercially available under the tradename VERV from American Ingredients Co., Kansas City, MO.) being particularly useful.
- calcium stearoyl-2-lactylate such as the calcium stearoyl-2-lactylate commercially available under the tradename VERV from American Ingredients Co., Kansas City, MO.
- fatty acid ester salts which may be utilized include those selected from the group consisting of lithium stearoyl lactylate, potassium stearoyl lactylate, rubidium stearoyl lactylate, cesium stearoyl lactylate, francium stearoyl lactylate, sodium palmityl lactylate, lithium palmityl lactylate, potassium palmityl lactylate, rubidium palmityl lactylate, cesium palmityl lactylate, francium palmityl lactylate, sodium olelyl lactylate, lithium olelyl lactylate, potassium olelyl lactylate, rubidium olelyl lactylate, cesium olelyl lactylate, and francium olelyl lactylate.
- the amount of fatty acid component can range in an amount from about 5 percent to about 50 percent by weight of the total coating composition. Typically, the fatty acid component may be present in an amount from about 10 percent to about 20 percent by weight of the total coating compositions.
- the coating composition contains one or more bioactive agents.
- bioactive agent as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye.
- a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes.
- bioactive agents examples include antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
- Suitable antimicrobial agents which may be included as a bioactive agent in the bioactive coating of the present disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin
- bioactive agents which may be included as a bioactive agent in the coating composition applied in accordance with the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g.
- oxybutynin antitussives
- bronchodilators cardiovascular agents such as coronary vasodilators and nitroglycerin
- alkaloids analgesics
- narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like
- non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like
- opioid receptor antagonists such as naltrexone and naloxone
- anti-cancer agents anti-convulsants; anti-emetics
- antihistamines anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like
- prostaglandins and cytotoxic drugs estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants;
- lymphokines monokines, chemokines
- blood clotting factors hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons ( ⁇ -IFN, ( ⁇ -IFN and ⁇ -MN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligon
- a single bioactive agent may be utilized to form the coating composition or, in alternate embodiments, any combination of bioactive agents may be utilized to form the coating composition applied in accordance with the present disclosure.
- the amounts of bioabsorbable coating composition to be applied to the suture vary depending upon the specific construction of the suture, the size and the material of this construction.
- the coating composition applied to an unfilled suture will constitute from about 1.0 to about 3.0 percent by weight of the coated suture, but the amount of coating composition on may range from as little as about 0.5 percent, by weight, to as much as 4.0 percent or higher.
- amounts of coating composition will generally vary from about 0.5% to 2.0% with as little as 0.2% to as much as 3.0%.
- it is generally preferred to apply the minimum amount of coating composition consistent with good surface lubricity and/or knot tie-down characteristics and this level of coating add on is readily determined experimentally for any particular suture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Textile Engineering (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
Abstract
System and method for coating a suture line are disclosed. The system includes a first guide positioned to orient the suture line for entry into a coating tube. The system also includes a coating tube having an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube. The coating tube includes a fill opening through which a coating composition is introduced into the coating tube to a level sufficient to submerge a portion of the suture line. The system further includes a second guide positioned to orient the suture line exiting from the dryer.
Description
- The present application claims the benefit of and priority to U.S. Provisional Application Ser. No. 60/752,685 filed on Dec. 20, 2005, the entire disclosure of which is incorporated by reference herein.
- 1. Technical Field
- The present disclosure relates generally to filament coating systems and methods, more specifically to systems and methods for coating sutures.
- 2. Background of Related Art
- Surgical sutures are primarily used during surgery to stitch together sections of tissue to aid in post-surgical healing. Sutures are often coated with various substances to improve their knot tie-down characteristics. In addition, coating increases suture's surface lubricity which reduces the friction associated with passing of the suture through the tissue, thereby reducing tissue trauma. Conventionally, suture coatings have been applied by dipping, bushing, wiping, spraying or drip coating. Dip coating involves submergence of a suture line into a coating composition contained in a vessel. Typically, dip coating involves the use of multiple guiding means (e.g., rollers) to pass the suture through the coating composition. For instance, a horizontally passing suture needs to be directed downward into and upward out of the vessel containing the coating composition. Thus, at least one of the guiding roller(s) is positioned within the coating vessel, in contact with the suture before the line is dried. This contact by the roller frequently removes coating material from the suture, thereby reducing the effectiveness of the coating.
- Coating has also been accomplished using filling heads. This method involves passing a suture line through a V-shaped notch. Coating composition injected into the notch contacts and coats the suture line. The suture line does not come in contact with guiding rollers until after the coating dries. Although the coating system using filling heads provides more consistent coating for the suture line, the contact time for coating solution to penetrate into suture is significantly less (e.g., less that 0.1 second) than that provided by the conventional dipping coating mechanisms.
- Therefore, there is a need for a coating system which allows for more consistent coating at high contact time.
- A system and method for coating a suture line are disclosed. The system includes an elongated coating tube having coater heads disposed at both ends thereof. The suture line is fed into the coating tube through an opening in one of the coater heads and exits the coating tube through an opening in the other coater head. Guide rollers that contact the un-coated suture ensure alignment of the suture line as it enters the coating tube. The coating tube is filled with a coating composition to a level above the entry point of the suture line. The composition pours through the openings of the coating tube and is collected by the coater heads so that it is circulated during the coating process to ensure proper ratio of coating agent to solvent. After exiting the coating tube, the suture line passes through a dryer and then is guided by a set of rollers to a winding roll. Then, the suture contacts guide rollers only after exiting the dryer, thereby helping to ensure a uniform coating.
- According to one embodiment of the present disclosure, a system for coating a suture line is disclosed. The system includes a first guide positioned to orient the suture line for entry into a coating tube. The system also includes a coating tube having an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube. The coating tube includes a fill opening through which a coating composition is introduced into the coating tube to a level sufficient to submerge a portion of the suture line. The system further includes a second guide positioned to orient the suture line exiting from the dryer.
- According to another embodiment of the present disclosure, a method for coating at least one suture line is disclosed. The method includes the step of orienting the suture line through a first guide for entry into a coating tube. The coating tube includes an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube. The coating tube further includes one or more fill openings through which a coating composition is introduced into the coating tube a level sufficient to submerge a portion of the suture line. The method also includes the steps of submerging the suture line in the coating composition filling the coating tube as well as orienting the suture line exiting from the dryer through a second guide.
- According to a further embodiment of the present disclosure, a system for coating at least one suture line is disclosed. The system includes a first guide positioned to orient the suture line for entry into a coating tube having an inlet opening to admit the suture line passing through the first guide and an outlet opening through which the suture line exits the coating tube. The coating tube also includes at least one fill opening through which a coating composition is introduced into the coating tube to at least a level sufficient to submerge at least one portion of the suture line, such that the coating composition flows out through at least one of the inlet and outlet openings. The system also includes at least one coater head disposed at each of end of the coating tube, the first and second coater head configured to collect the coating composition flowing through the inlet and outlet openings and a second guide positioned to orient the suture line exiting the coating tube.
- The above and other aspects, features, and advantages of the present disclosure will become more apparent in light of the following detailed description when taken in conjunction with the accompanying drawings in which:
-
FIG. 1 is a schematic diagram of a dip suture coating system according to one embodiment of the present disclosure; -
FIG. 2 is a schematic diagram of a dip coater according to the present disclosure; -
FIG. 3 is a schematic diagram of a distal coater head useful in embodiments of coating systems according to the present disclosure; -
FIG. 4 is a sectional view of a dip coating tube according to the present disclosure; and -
FIG. 5 is a flow diagram of a method for coating a suture line according to the present disclosure. - Preferred embodiments of the present disclosure will be described herein below with reference to the accompanying drawings. In the following description, well-known functions or constructions are not described in detail to avoid obscuring the present disclosure in unnecessary detail.
- The present disclosure provides for a horizontal dip coating system. The system includes one or more input winders inputting a suture line into a dip coater using a first set of one or more guiding rollers. The dip coater includes a coating tube positioned horizontally with a coater head disposed at proximal and distal ends thereof. The coating tube and the coater heads include openings through its centers to allow for the suture line to pass horizontally therethrough. A coating composition fills the coating tube above the openings of the coating tube through which the suture line passes to coat the line. Any coating composition that leaks out of the coating tube is collected by the coater heads. The coating composition is injected at a higher rate than it leaks out to maintain the composition level therein. In addition, the coating composition collected by the coater heads is circulated throughout the dip coater. In some embodiments, where the coating composition includes solvent carrier and coating agent, solvent content of the coating composition is-monitored and adjusted to ensure that a predetermined ratio of coating agent to solvent is maintained. Upon coating, the suture line is dried and thereafter the line is guided by a second set of one or more rollers to winding rolls.
-
FIG. 1 shows a horizontal dip coating system 1 according to the present disclosure for coating a plurality of suture lines simultaneously. The coating system 1 includes at least one input winder 2 for passing at least onesuture line 10 through adip coater 3, anair wiper 5, adryer 6, and anair cooler 7. Thereafter theline 10 is wound by at least one take-up winder 8, which may be part of a pull-overloading station 9. It is envisioned that the pull-over loading station pulls theline 10 through the coating system 1. As theline 10 passes through thedip coater 3 it is submerged in a coating composition in order to absorb coating materials. As will be appreciated by those skilled in the art, the coating system shown inFIG. 1 includes multiple input winders and multiple take-up winders. Also, it is contemplated that each input winder and/or take-up winder may handle one or more than one suture lines (e.g., inFIG. 1 each winder handles two suture lines). - The input winder(s) 2 disperses the
line 10 which may be a monofilament or a multifilament braided suture. Prior to dispersing, theline 10 may be prepared for coating which may involve calendaring theline 10 to facilitate penetration of the coating composition into the interstices of the braid suture, especially where the present system is used to apply a second or third composition to the suture line. An example of a calendaring apparatus and method thereof is disclosed by commonly owned U.S. Pat. No. 5,312,642 entitled “Method and Apparatus for Calendering and Coating/Filling Sutures” which is hereby incorporated by reference in its entirety herein. - The system 1 also includes the
air wiper 5 and theair cooler 7. Theair wiper 5 is positioned between thedip coater 3 and thedryer 6 and is configured to blow gas (e.g., air, nitrogen, etc.) on the passingline 10 to blow off excess composition. Theair cooler 7 is positioned between thedryer 6 and the take-up winder 8 and is configured to blow cool air on theline 10 to provide cooling for the dried line. -
FIG. 2 shows in more detail adip coater 3 and thedryer 6 in accordance with an embodiment of the present disclosure. Theline 10 is passed through thedip coater 3 so that it is immersed in a coating composition. Theline 10 is guided into thedip coater 3 around a first set of rollers 13 (e.g.,rollers 12 and 14) and passed horizontally through acoating tube 24 which is filled with acoating composition 31 containing the dissolved coating agent. It is envisioned that thedip coater 3 may be configured to coat a plurality oflines 10. For example, thedip coater 3 may have a plurality ofcoating tubes 24 corresponding to the number oflines 10. Alternatively, the coating tube 4 may be substituted by a container configured to coatmultiple lines 10. - As the
line 10 is passed horizontally through thecoating tube 24, coating composition is applied to theline 10. Thecoating tube 24 is positioned horizontally and may have a cylindrical shape and may be approximately 1′ to 10′ in length. Typically, the coating tube is 3′ to 5′ long. In addition, thecoating tube 24 is preferably manufactured from stainless steel material that does not react with the coating composition. For example, the coating tube may be glass or glass-lined. In addition, if a metal tube is used, it may be desirable to passivate the tube to reduce its reactivity. Passivation methods and materials are within the purview of those skilled in the art. The outer diameter of tube can vary depending on a number of factors such as the number of filaments being treated, the particular coating composition being applied and the desired contact time between the composition and the suture line. Those skilled in the art will appreciate that the cylindrical shape is merely only one embodiment of thecoating tube 24 and that it may have a variety of shapes (e.g., rectangular, triangular, or hexagonal cross-sectional shapes, etc.). - The
line 10 enters thecoating tube 24 through aproximal coater head 18 which is discussed in more detail below with reference to adistal coater head 20, both of which have a circular cross section. It is envisioned that theline 10 passes throughdip coater 3 through anopening 91 of theproximal coater head 18, anopening 92 of thecoating tube 24, anopening 93 of thecoating tube 24 and anopening 94 of thedistal coater head 20. The 91, 92, 93, 94 are preferably drilled through the center ofopenings 95, 96, 97, 98 respectively, of ceramic eyelets disposed within the proximal and distal coater heads 18, 20 and thesurfaces coating tube 24 as shown inFIG. 3 and discussed in more detail below. The openings may be drilled in a plurality of ways (e.g., a laser) to achieve a straight path for theline 10 through thedip coater 3. - The
coating tube 24 is filled with acoating composition 31 through asupply tube 56 which is connected thereto viaadapter 60 having a male national pipe thread (MNPT) or another type of connecting means. Theadapter 60 may be coupled to thecoating tube 24 at an angle (e.g., a 135° angle) with the longitudinal axis of thecoating tube 24 at the top portion thereof. Those skilled in the art will appreciate that the tubing used to interconnect the components of the dip coater 3 (e.g., thesupply tube 56 and other tubing discussed below) may be manufactured from any materials allowing the tubing to be flexible as well as chemically inert to a variety of organic solvents. In one embodiment, thesupply tube 56 is made from PTFE and has a ⅜″ diameter. Thecoating composition 31 is carried into thecoating tube 24 via a circulatingpump 34 which withdraws thecomposition 31 from atank 28 through atube 58. Thetank 28 preferably includes a stirring device, such as amagnetic stirrer driver 26 positioned thereunder, to prevent settling or other separation of the components of the coating composition. -
FIG. 3 shows a cross sectional view of thedistal coater head 20 along the vertical axis of thecoating tube 24. Thecoating tube 24 is filled with thecomposition 31 to a level which is at least above the line 10 (e.g., above the center of the coating tube 24) to ensure that theline 10 is immersed in thecomposition 31 as theline 10 passes through thecoating tube 24. Since thecomposition 31 fills thecoating tube 24 above theopening 93,composition 31 may leak therethrough and be collected in the proximal and distal coater heads 18, 20. As a result ofcomposition 31 leaking out of thecoating tube 24, the in-flow must equal or exceed out-flow. Therefore, thecomposition 31 will be circulated (e.g., continually supplied into the coating tube 24) to maintain a steady state, where the level of thecomposition 31 is continuously above the 92, 93.openings - The
assembly 20 includes a removable reducingtee 80 configured to drain leakingcomposition 31. The reducingtee 80 can advantageously have an outer diameter larger than the outer diameter of thecoating tube 24 so that thetee 80 fits over thecoating tube 24. Thereturn adapter 22 is the reducing portion of the reducingtee 80 and preferably includes an MNPT connection. - The
removable tee 80 is connected to thecoating tube 24. Thedistal coater head 20 includes two 72, 74. Theceramic eyelets ceramic eyelet 72 is positioned at the distal end of thecoating tube 24 within the reducingtee 80 and theceramic eyelet 74 is attached at the distal end of the reducingtee 80. The 72, 74 are designed to optimize alignment of theceramic eyelets 93, 94 while minimizing the solvent lost during the coating process as discussed in more detail below. Those skilled in the art will appreciate that theopenings proximal coater head 18 includes the same components (e.g., ceramic eyelet, o-ring, etc.) assembled in the same manner as discussed above with regard to thedistal coater head 20. - With reference to
FIG. 2 , thecomposition 31 out-flows through 21, 22 coupled to the bottom portion of the proximal and distal coater heads 18, 20 respectively and returnreturn adapters 45, 42 to atubes return tank 32. In addition, thereturn tank 32 collects anyexcess composition 31 present in thecoating tube 24 through anoverflow adapter 40 which is coupled to the upper portion thereof. Upon reaching theoverflow adapter 40, theexcess coating composition 31 flows through areturn tube 44 to thereturn tank 32 and mixes withreturn composition 33. The outlet ofoverflow adapter 40 is also used to determine when thecomposition 31 filled thecoating tube 24 to the desired level. Theoverflow adapter 40 is positioned above the 91, 92, 93, 94 hence whenopenings composition 31 reaches theoverflow adapter 40 and flows therethrough and into thereturn tank 32. This ensures that thesuture line 10 is submerged inside thecoating tube 24. There can bemultiple overflow adapters 40 positioned along thecoating tube 24 for higher recirculation rate. -
FIG. 4 shows a cross sectional view along the section line 4 of thecoating tube 24.Adapter 60 andadapter 54 are shown positioned on the upper portion of thecoating tube 24 while thedrain valve 46 is positioned on the bottom portion thereof. In addition, theoverflow adapter 40 is positioned on the upper portion of thecoating tube 24 as well, slightly below the 54, 60. Theadapters drain valve 46 may be used toempty coating tube 24 of thecoating composition 31 upon shut down of the coating system 1 for maintenance or once the coating process is finished. - It is also envisioned that the
return composition 33 may be recycled during the coating process. Typically, a portion of any volatile solvent in the coating composition may evaporate during the coating process beforeexcess composition 31 flows to thereturn tank 32. Thereturn composition 33 is contained within the coating system 1 by a plurality of tubes and adapters discussed above to contain thereturn composition 33 and to minimize solvent loss and vapor escape. Some vapor which does escape is vented through vent headers (not shown) installed above thecoating tube 24. - In order for the
return composition 33 to be recycled, it must be verified that the desired coating agent composition is maintained. With reference toFIG. 2 , acontroller 48 can be connected to thereturn tank 32 and configured to test the density and/or viscosity of thereturn composition 33 using, e.g., a mass flow meter. If the density/viscosity of thereturn composition 33 exceeds a predetermined level (e.g., density of the original composition 31) then thecontroller 48 signals that the composition needs to be adjusted e.g., by injecting additionalsolvent carrier 35 directly into thecoating tube 24 or into thereturn tank 32. - In one embodiment, the
controller 48 is electrically connected to a solvent pump 96 (e.g., solvent supply means) which injects solvent 35 into thecoating tube 24 and a control valve 50 adjusts the flow of the solvent 35 into thereturn tank 32. The solvent 35 can be injected into thecoating tube 24 through thesolvent adapter 54 connected to thesolvent tank 36 through atube 52. Thesolvent adapter 54 is positioned at an angle (e.g., a 45° angle) with the longitudinal axis of thecoating tube 24 at the top portion thereof while thedrain valve 46 is positioned on the bottom portion thereof. In addition, thereturn tank 32 includes a magnetic stirrer driver 30 to maintain uniformity of the coating composition throughout thereturn composition 33 and to mix any added solvent 35. Furthermore,return tank 32 supplies thereturn composition 33 totank 28 where it is recycled and continually pumped into thecoating tube 24. -
FIG. 5 shows a method for coating thesuture line 10 using the coating system 1 of the present disclosure. Instep 150 thecoating tube 24 is filled with thecomposition 31 above the 92, 93 to ensure that as theopenings line 10 is submerged in thecomposition 31. Thecomposition 31 is continually fed into thecoating tube 24 at a rate which is equal to or slightly exceeds the rate at which thecomposition 31 leaks through the 92, 93. This allows the level of theopenings composition 31 to stay above the 92, 93 despite the loss of theopenings composition 31. Thus, only the level of thecomposition 31 must be controlled during the coating process, whereas, conventional coating techniques, which depend on point coating, require precise control of the flow rate of the coating composition. - In
step 152,excess composition 31 is collected. This is accomplished by collecting thecomposition 31 from the proximal and distal coater heads 18, 20 which are configured to catch excess liquid and from theoverflow adapter 40 which prevents overfilling of thecoating tube 24 by providing a flow path for anyexcess composition 31. Theexcess composition 31 flows to thereturn tank 32. - Since the coating system 1 relies on constant supply of the
composition 31 to thecoating tube 24 thecomposition 31 must be circulated. As discussed above, in some embodiments the coating process involves application of coating agent dissolved in a volatile organic solvent. Therefore, solvent may need to be replenished to maintain the desired coating agent levels within thecomposition 31. Instep 154, thecontroller 48 analyzes the density/viscosity ofreturn composition 33 to determine whether additional solvent 35 needs to be added. If the density is above the desired limit (e.g., the coating agent to solvent ratio within thereturn composition 33 is larger than that ratio within the composition 31) then instep 156, thecontroller 48 adjusts the solvent content. Adjustment of solvent level can be accomplished by signaling thesolvent pump 96 which injects the solvent 35 into thecoating tube 24 and/or opening the control valve 50 to add solvent 35 into thereturn composition 33. Thereturn composition 33 is then added intotank 28 from where it is continuously injected intocoating tube 24. - Each portion of the
suture line 10 should reside within thecoating tube 24 approximately between 0.5 second to 10 minutes, preferably the residence time is about 1 minute. As theline 10 thedip coater 3 theline 10 enters thedryer 6 and instep 158, theline 10 is dried. The drying temperature depends on the coating composition used and may range approximately between the ambient room temperature (e.g., 25° C.) at the low extreme and above 100° C. at the upper extreme. It is also envisioned that thedryer 6 uses heated gas (e.g., air, nitrogen, etc.) to dry theline 10. Instep 160, theline 10 is cooled by theair cooler 7, which blows cool air onto the driedline 10 and thereafter theline 10 is guided by a second set of rollers 39 (e.g., a roller 38) into the winder 8 where it is wound. - The present disclosure allows the
line 10 to avoid physical contact with various machine parts during the coating process (e.g., guiding rollers). Theline 10 comes in contact only with the coating composition between the time it is fed into thedip coater 3 and the time it is wound on the winder 8. This is due to the horizontal positioning of thecoating tube 24 and the horizontal orientation of theline 10 therethrough, which allows theline 10 to avoid physical contact with components by using a minimal amount of guiding mechanisms (e.g., guidingrollers 13, 39) - Any coating composition known to be useful for coating medical devices may be applied to a medical device using the present methods and apparatus. The coating composition can be a solution, dispersion, emulsion containing, for example, one or more polymeric materials and/or one or more bioactive agents.
- In some embodiments, the coating composition includes a polymer, or a combination of polymers. The polymer is most suitably biocompatible, including polymers that are non-toxic, non-inflammatory, chemically inert, and substantially non-immunogenic in the applied amounts. The polymer may be either bioabsorbable or biostable. A bioabsorbable polymer breaks down in the body. Bioabsorbable polymers are gradually absorbed or eliminated by the body by hydrolysis, metabolic process, bulk, or surface erosion. Examples of bioabsorbable materials include but are not limited to polycaprolactone (PCL), poly-D, L-lactic acid (DL-PLA), poly-L-lactic acid (L-PLA), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly (amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates. Biomolecules such as heparin, fibrin, fibrinogen, cellulose, starch, and collagen are typically also suitable. A biostable polymer does not break down in the body, and thus a biostable polymer is present in the body for a substantial amount of time after implantation. Examples of biostable polymers include PARYLENE™, PARYLAST™, polyurethane (for example, segmented polyurethanes such as BIOSPAN™), polyethylene, polyethlyene teraphthalate, ethylene vinyl acetate, silicone, polyethylene oxide, and polytetrafluoroethylene (PTFE).
- In some embodiments, the coating compositions of the present disclosure may also include a fatty acid component that contains a fatty acid or a fatty acid salt or a salt of a fatty acid ester. Suitable fatty acids may be saturated or unsaturated, and include higher fatty acids having more than about 12 carbon atoms. Suitable saturated fatty acids include, for example, stearic acid, palmitic acid, myristic acid and lauric acid. Suitable unsaturated fatty acids include oleic acid, linoleic acid, and linolenic acid. In addition, an ester of fatty acids, such as sorbitan tristearate or hydrogenated castor oil, may be used.
- Suitable fatty acid salts include the polyvalent metal ion salts of C6 and higher fatty acids, particularly those having from about 12 to 22 carbon atoms, and mixtures thereof. Fatty acid salts including the calcium, magnesium, barium, aluminum, and zinc salts of stearic, palmitic and oleic acids may be useful in some embodiments of the present disclosure. Particularly useful salts include commercial “food grade” calcium stearate which consists of a mixture of about one-third C16 and two-thirds C18 fatty acids, with small amounts of the C14 and C22 fatty acids.
- Suitable salts of fatty acid esters which may be included in the coating compositions applied in accordance with the present disclosure include calcium, magnesium, aluminum, barium, or zinc stearoyl lactylate; calcium, magnesium, aluminum, barium, or zinc palmityl lactylate; calcium, magnesium, aluminum, barium, or zinc olelyl lactylate; with calcium stearoyl-2-lactylate (such as the calcium stearoyl-2-lactylate commercially available under the tradename VERV from American Ingredients Co., Kansas City, MO.) being particularly useful. Other fatty acid ester salts which may be utilized include those selected from the group consisting of lithium stearoyl lactylate, potassium stearoyl lactylate, rubidium stearoyl lactylate, cesium stearoyl lactylate, francium stearoyl lactylate, sodium palmityl lactylate, lithium palmityl lactylate, potassium palmityl lactylate, rubidium palmityl lactylate, cesium palmityl lactylate, francium palmityl lactylate, sodium olelyl lactylate, lithium olelyl lactylate, potassium olelyl lactylate, rubidium olelyl lactylate, cesium olelyl lactylate, and francium olelyl lactylate.
- Where utilized, the amount of fatty acid component can range in an amount from about 5 percent to about 50 percent by weight of the total coating composition. Typically, the fatty acid component may be present in an amount from about 10 percent to about 20 percent by weight of the total coating compositions.
- In some embodiments, the coating composition contains one or more bioactive agents. The term “bioactive agent”, as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye. Alternatively a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes.
- Examples of classes of bioactive agents which may be utilized in accordance with the present disclosure include antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
- Suitable antimicrobial agents which may be included as a bioactive agent in the bioactive coating of the present disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil,
nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the present disclosure. - Other bioactive agents which may be included as a bioactive agent in the coating composition applied in accordance with the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
- Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-MN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; and ribozymes.
- A single bioactive agent may be utilized to form the coating composition or, in alternate embodiments, any combination of bioactive agents may be utilized to form the coating composition applied in accordance with the present disclosure.
- The amounts of bioabsorbable coating composition to be applied to the suture vary depending upon the specific construction of the suture, the size and the material of this construction. In general, the coating composition applied to an unfilled suture will constitute from about 1.0 to about 3.0 percent by weight of the coated suture, but the amount of coating composition on may range from as little as about 0.5 percent, by weight, to as much as 4.0 percent or higher. For a preferred filled (i.e., containing a storage stabilizing agent) braided suture, amounts of coating composition will generally vary from about 0.5% to 2.0% with as little as 0.2% to as much as 3.0%. As a practical matter and for reasons of economy and general performance, it is generally preferred to apply the minimum amount of coating composition consistent with good surface lubricity and/or knot tie-down characteristics and this level of coating add on is readily determined experimentally for any particular suture.
- The described embodiments of the present disclosure are intended to be illustrative rather than restrictive, and are not intended to represent every embodiment of the present disclosure. Various modifications and variations can be made without departing from the spirit or scope of the disclosure as set forth in the following claims both literally and in equivalents recognized in law.
Claims (19)
1. A system for coating a suture line comprising:
a coating tube;
a first guide positioned to orient the suture line for entry into the coating tube; and
a second guide positioned to orient the suture line exiting the coating tube,
wherein the coating tube possesses an inlet opening to admit the suture line passing through the first guide and an outlet opening through which the suture line exits the coating tube, and the coating tube includes at least one fill opening through which a coating composition is introduced into the coating tube to at least a level sufficient to submerge at least one portion of the suture line.
2. A system as in claim 1 , wherein the coating tube further comprises at least one coater head disposed at each end of the coating tube, and the at least one coater head is configured to collect the coating composition flowing through the inlet and outlet openings.
3. A system as in claim 2 , further comprising:
a return composition tank to collect the coating composition flowing through the inlet and outlet openings.
4. A system as in claim 3 , further comprising:
a controller to determine a ratio of at least one coating agent and at least one solvent carrier in the coating composition flowing through the inlet and outlet openings; and a solvent supply means for adding the solvent to the coating composition as a fumction of the ratio.
5. A system as in claim 4 , wherein the solvent supply means supply the solvent to the return composition tank and the coating tube.
6. A system as in claim 1 , further comprising a dryer which dries the suture line at a temperature of from about to 25° C. to about 100° C.
7. A method for coating a suture line comprising:
orienting the suture line through a first guide for entry into a coating tube, the coating tube possessing an inlet opening to admit the suture line and an outlet opening through which the suture line exits the coating tube, the coating tube also possessing at least one fill opening through which a coating composition is introduced into the coating tube to at least a level sufficient to submerge at least one portion of the suture line;
submerging the suture line in the coating composition filling the coating tube; and
orienting the suture line exiting from the coating tube through a second guide.
8. A method as in claim 7 , wherein the coating tube further includes at least one coater head disposed at each end of the coating tube and the at least one coater head is configured to collect the composition flowing through the inlet and outlet openings.
9. A method as in claim 8 , further comprising the step of:
collecting the composition flowing through the inlet and outlet openings in a return composition tank.
10. A method as in claim 9 , further comprising the step of:
determining a ratio of a coating agent and a solvent in the coating composition flowing through the inlet and outlet openings; and
adding the solvent to the coating composition as a function of the ratio.
11. A method as in claim 10 , wherein the adding the solvent step includes supplying the solvent to the return composition tank and the coating tube.
12. A method as in claim 7 , further comprising drying the suture line exiting from the coating tube at a temperature in the range of from about 25° C. to about 100° C.
13. A method as in claim 12 , ftrther comprising the steps of:
blowing a gas onto the suture line exiting the coating tube prior to drying; and
cooling the suture line prior to passing the at least one suture line through the second guide.
14. A method as in claim 7 , wherein the step of submerging the suture line includes determining the level sufficient to submerge and wet the at least one suture line.
15. A system for coating a suture line, comprising:
a coating tube possessing an inlet opening to admit the suture line into the coating tube and an outlet opening through which the suture line exits the coating tube, the coating tube possessing at least one fill opening through which a coating composition is introduced into the coating tube to at least a level sufficient to submerge at least one portion of the suture line;
a first guide positioned to orient the suture line for entry into the coating tube;
a second guide positioned to orient the suture line exiting the coating tube; and
at least one coater head disposed at each of end of the coating tube,
wherein the coating composition in the coating tube flows out through at least one of the inlet and outlet openings and the at least one coater head is configured to collect the coating composition flowing through the inlet and outlet openings.
16. A system as in claim 15 , further comprising:
a return composition tank to collect the coating composition flowing through the inlet and outlet openings.
17. A system as in claim 16 , further comprising:
a controller to determine a ratio of at least one coating agent and at least one solvent carrier in the coating composition flowing through the inlet and outlet openings; and
a solvent supply means for adding the solvent to the coating composition as a function of the ratio.
18. A system as in claim 17 , wherein the solvent supply means supply the solvent to the return composition tank and the coating tube.
19. A system as in claim 15 , further comprising a dryer which dries the suture line at a temperature in the range of from about 25° C. to about 100° C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/638,982 US20070141245A1 (en) | 2005-12-20 | 2006-12-14 | System and method for coating filaments |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75268505P | 2005-12-20 | 2005-12-20 | |
| US11/638,982 US20070141245A1 (en) | 2005-12-20 | 2006-12-14 | System and method for coating filaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20070141245A1 true US20070141245A1 (en) | 2007-06-21 |
Family
ID=37847229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/638,982 Abandoned US20070141245A1 (en) | 2005-12-20 | 2006-12-14 | System and method for coating filaments |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070141245A1 (en) |
| EP (2) | EP2204124B1 (en) |
| DE (1) | DE602006018415D1 (en) |
| ES (2) | ES2373860T3 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016890A1 (en) * | 2008-07-17 | 2010-01-21 | Steve Tsai | Spool Dip And Overcoat Process For Medical Devices |
| US20110024043A1 (en) * | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
| US20180353173A1 (en) * | 2015-12-03 | 2018-12-13 | Ramsey KINNEY | Coated suture system for healing augmentation of soft tissue repair and reconstruction |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075020A1 (en) * | 2008-09-25 | 2010-03-25 | Tyco Healthcare Group Lp | Methods for coating filaments |
| NZ626274A (en) | 2010-05-04 | 2015-03-27 | Ethicon Llc | Laser cutting system and methods for creating self-retaining sutures |
| CN102698315B (en) * | 2012-06-26 | 2014-01-15 | 单县润康缝合材料有限公司 | Coating method of antibacterial surgical suture made of high molecular absorbable material |
Citations (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583267A (en) * | 1947-12-30 | 1952-01-22 | British Cotton Ind Res Assoc | Apparatus for continuously applying a prescribed amount of liquid composition to a moving linear material |
| US2787980A (en) * | 1953-07-21 | 1957-04-09 | American Viscose Corp | Liquid applicator for running strand |
| US3338738A (en) * | 1963-08-06 | 1967-08-29 | Hooker Chemical Corp | Method and apparatus for applying a halogenatedhydrocarbon solventcontaining enamel to wire |
| US3461011A (en) * | 1965-02-12 | 1969-08-12 | Rte Corp | Method and apparatus for wet winding coil assemblies for transformers |
| US3599600A (en) * | 1969-12-23 | 1971-08-17 | Westinghouse Electric Corp | Control system for coating continuous webs |
| US3724088A (en) * | 1970-01-21 | 1973-04-03 | Omnium De Prospective Ind Sa | Process using shock waves for the continuous treatment of threads |
| US3905327A (en) * | 1973-01-15 | 1975-09-16 | Opi Textile | Apparatus for the impregnation with a treating liquid and for the squeezing of a textile product running continuously |
| US3906757A (en) * | 1971-06-14 | 1975-09-23 | Unitika Ltd | Apparatus for continuous dyeing of yarns |
| US4470941A (en) * | 1982-06-02 | 1984-09-11 | Bioresearch Inc. | Preparation of composite surgical sutures |
| US4584347A (en) * | 1982-09-30 | 1986-04-22 | Allied Corporation | Modified polyolefin fiber |
| US4911927A (en) * | 1988-11-14 | 1990-03-27 | Hill Ira D | Method and apparatus for adding chemotherapeutic agents to dental floss |
| US4926661A (en) * | 1989-03-15 | 1990-05-22 | E. I. Du Pont De Nemours And Company | Yarn finish applicator |
| US4994303A (en) * | 1988-03-21 | 1991-02-19 | Garlock, Inc. | Fiber impregnation process |
| US5072472A (en) * | 1987-12-07 | 1991-12-17 | Passap Knitting Machines, Inc. | Continuous process for dyeing a textile thread, and installation for the implementation of this process |
| US5088441A (en) * | 1990-08-23 | 1992-02-18 | Belport Co., Inc. | Cord impregnator |
| US5104398A (en) * | 1990-01-30 | 1992-04-14 | Deutsche Institute fur Textil- und Faserforschung Stuttgart - Stiftung des offentlichen Rechts | Process for the treatment of a surgical suturing thread and surgical suturing thread |
| US5217485A (en) * | 1991-07-12 | 1993-06-08 | United States Surgical Corporation | Polypropylene monofilament suture and process for its manufacture |
| US5269807A (en) * | 1992-08-27 | 1993-12-14 | United States Surgical Corporation | Suture fabricated from syndiotactic polypropylene |
| US5279783A (en) * | 1992-01-30 | 1994-01-18 | United States Surgical Corporation | Process for manufacture of polyamide monofilament suture |
| US5284489A (en) * | 1992-08-19 | 1994-02-08 | United States Surgical Corporation | Filament fabricated from a blend of ionomer resin and nonionic thermoplastic resin |
| US5312642A (en) * | 1991-02-08 | 1994-05-17 | United States Surgical Corporation | Method and apparatus for calendering and coating/filling sutures |
| US5423859A (en) * | 1991-11-13 | 1995-06-13 | United States Surgical Corporation | Jet entangled suture yarn and method for making same |
| US5709910A (en) * | 1995-11-06 | 1998-01-20 | Lockheed Idaho Technologies Company | Method and apparatus for the application of textile treatment compositions to textile materials |
| US5802649A (en) * | 1996-02-12 | 1998-09-08 | Fypro | Method and apparatus for dyeing a traveling textile strand |
| US6180310B1 (en) * | 2000-08-14 | 2001-01-30 | Xerox Corporation | Dip coating process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61502379A (en) * | 1984-06-14 | 1986-10-23 | バイオリサ−チ インコ−ポレイテツド | composite surgical suture |
| US5817129A (en) * | 1996-10-31 | 1998-10-06 | Ethicon, Inc. | Process and apparatus for coating surgical sutures |
| US6183499B1 (en) * | 1998-09-11 | 2001-02-06 | Ethicon, Inc. | Surgical filament construction |
-
2006
- 2006-12-14 US US11/638,982 patent/US20070141245A1/en not_active Abandoned
- 2006-12-19 EP EP10003090A patent/EP2204124B1/en not_active Not-in-force
- 2006-12-19 ES ES10003090T patent/ES2373860T3/en active Active
- 2006-12-19 EP EP06026288A patent/EP1800609B1/en not_active Not-in-force
- 2006-12-19 DE DE602006018415T patent/DE602006018415D1/en active Active
- 2006-12-19 ES ES06026288T patent/ES2358759T3/en active Active
Patent Citations (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583267A (en) * | 1947-12-30 | 1952-01-22 | British Cotton Ind Res Assoc | Apparatus for continuously applying a prescribed amount of liquid composition to a moving linear material |
| US2787980A (en) * | 1953-07-21 | 1957-04-09 | American Viscose Corp | Liquid applicator for running strand |
| US3338738A (en) * | 1963-08-06 | 1967-08-29 | Hooker Chemical Corp | Method and apparatus for applying a halogenatedhydrocarbon solventcontaining enamel to wire |
| US3461011A (en) * | 1965-02-12 | 1969-08-12 | Rte Corp | Method and apparatus for wet winding coil assemblies for transformers |
| US3599600A (en) * | 1969-12-23 | 1971-08-17 | Westinghouse Electric Corp | Control system for coating continuous webs |
| US3724088A (en) * | 1970-01-21 | 1973-04-03 | Omnium De Prospective Ind Sa | Process using shock waves for the continuous treatment of threads |
| US3906757A (en) * | 1971-06-14 | 1975-09-23 | Unitika Ltd | Apparatus for continuous dyeing of yarns |
| US3905327A (en) * | 1973-01-15 | 1975-09-16 | Opi Textile | Apparatus for the impregnation with a treating liquid and for the squeezing of a textile product running continuously |
| US4470941A (en) * | 1982-06-02 | 1984-09-11 | Bioresearch Inc. | Preparation of composite surgical sutures |
| US4584347A (en) * | 1982-09-30 | 1986-04-22 | Allied Corporation | Modified polyolefin fiber |
| US5072472A (en) * | 1987-12-07 | 1991-12-17 | Passap Knitting Machines, Inc. | Continuous process for dyeing a textile thread, and installation for the implementation of this process |
| US4994303A (en) * | 1988-03-21 | 1991-02-19 | Garlock, Inc. | Fiber impregnation process |
| US4911927A (en) * | 1988-11-14 | 1990-03-27 | Hill Ira D | Method and apparatus for adding chemotherapeutic agents to dental floss |
| US4926661A (en) * | 1989-03-15 | 1990-05-22 | E. I. Du Pont De Nemours And Company | Yarn finish applicator |
| US5104398A (en) * | 1990-01-30 | 1992-04-14 | Deutsche Institute fur Textil- und Faserforschung Stuttgart - Stiftung des offentlichen Rechts | Process for the treatment of a surgical suturing thread and surgical suturing thread |
| US5088441A (en) * | 1990-08-23 | 1992-02-18 | Belport Co., Inc. | Cord impregnator |
| US5312642A (en) * | 1991-02-08 | 1994-05-17 | United States Surgical Corporation | Method and apparatus for calendering and coating/filling sutures |
| US5217485A (en) * | 1991-07-12 | 1993-06-08 | United States Surgical Corporation | Polypropylene monofilament suture and process for its manufacture |
| US5423859A (en) * | 1991-11-13 | 1995-06-13 | United States Surgical Corporation | Jet entangled suture yarn and method for making same |
| US5279783A (en) * | 1992-01-30 | 1994-01-18 | United States Surgical Corporation | Process for manufacture of polyamide monofilament suture |
| US5284489A (en) * | 1992-08-19 | 1994-02-08 | United States Surgical Corporation | Filament fabricated from a blend of ionomer resin and nonionic thermoplastic resin |
| US5269807A (en) * | 1992-08-27 | 1993-12-14 | United States Surgical Corporation | Suture fabricated from syndiotactic polypropylene |
| US5709910A (en) * | 1995-11-06 | 1998-01-20 | Lockheed Idaho Technologies Company | Method and apparatus for the application of textile treatment compositions to textile materials |
| US5802649A (en) * | 1996-02-12 | 1998-09-08 | Fypro | Method and apparatus for dyeing a traveling textile strand |
| US6180310B1 (en) * | 2000-08-14 | 2001-01-30 | Xerox Corporation | Dip coating process |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016890A1 (en) * | 2008-07-17 | 2010-01-21 | Steve Tsai | Spool Dip And Overcoat Process For Medical Devices |
| US20110024043A1 (en) * | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
| US20110027453A1 (en) * | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
| US12409515B2 (en) | 2009-07-02 | 2025-09-09 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
| US20180353173A1 (en) * | 2015-12-03 | 2018-12-13 | Ramsey KINNEY | Coated suture system for healing augmentation of soft tissue repair and reconstruction |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006018415D1 (en) | 2011-01-05 |
| EP2204124B1 (en) | 2011-09-28 |
| ES2373860T3 (en) | 2012-02-09 |
| EP1800609A1 (en) | 2007-06-27 |
| EP2204124A1 (en) | 2010-07-07 |
| ES2358759T3 (en) | 2011-05-13 |
| EP1800609B1 (en) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1825928B1 (en) | Pressurized dip coating method | |
| EP2204124B1 (en) | System for coating filaments | |
| EP2145692B1 (en) | Spool dip and overcoat process for medical devices | |
| US11717284B2 (en) | Surgical needle coatings and methods | |
| AU649514B2 (en) | Method and apparatus for calendering and coating/filling sutures | |
| US6187095B1 (en) | Process and apparatus for coating surgical sutures | |
| US9332982B2 (en) | Surgical needle coatings and methods | |
| US9266145B2 (en) | Surgical needle coatings and methods | |
| AU2008203378A1 (en) | Swirl coating applicator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: TYCO HEALTHCARE GROUP LP, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TSAI, STEVE;REEL/FRAME:018872/0185 Effective date: 20070125 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |